Connect with us

Health

Study suggests Pfizer COVID-19 vaccine only partially protects against Omicron – Toronto Sun

Published

 on


Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page.

Article content

The Omicron variant can partially evade protection from two doses of Pfizer and partner BioNTech’s COVID-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on Tuesday.

Advertisement

Article content

But the study showed that blood from people who had received two doses of the vaccine and had a prior infection was mostly able to neutralize the variant, suggesting that booster doses of the vaccine could help to fend off infection.

The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.

The World Health Organization classified it on Nov. 26 as a “variant of concern,” but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.

Alex Sigal, a professor at the research institute, said on Twitter there was “a very large drop” in neutralization of the Omicron variant relative to an earlier strain of COVID-19.

Advertisement

Article content

Advertisement

Article content

A separate lab test by virologist Sandra Ciesek of the University Hospital Frankfurt painted a somewhat bleaker picture.

Exposing the blood of vaccinated individuals to different virus variants, she found that the ability to mount an antibody response to Omicron in people who had three shots of BioNTech/Pfizer was up to 37 times lower than the response to Delta.

An antibody response to Omicron half a year after a two-shot regimen of Pfizer/BioNTech, Moderna or a mixed course of AstraZeneca/BioNTech was not even measurable, Ciesek added.

She posted only selected findings on Twitter, not including the number of samples, and the university said the paper had not yet been published.

“The set of data underscores that it makes sense to develop a vaccine that is adapted to Omicron,” Chiesek tweeted, adding that no conclusion could be drawn about protection against severe disease.

Advertisement

Article content

WHO’s chief scientist, Soumya Swaminathan, said a large drop in the antibody response of vaccinated people to Omicron had been expected.

“This does not mean the vaccine will not work – T-cell immunity (is) likely to persist,” she said on Twitter, referring to a cellular immune response that is believed to prevent severe disease as a second line of immune defence.

Advertisement

Article content

Researchers including Carsten Watzl of the German Society of Immunology and Penny Ward, visiting professor at King’s College London, said the findings underscored the need to get booster shots because a three-shot course would likely continue to protect against severe disease.

We apologize, but this video has failed to load.

Sigal’s lab tested blood from 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer reviewed.

Blood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.

“These results are better than I expected. The more antibodies you got, the more chance you’ll be protected from Omicron,” Sigal said on Twitter.

Advertisement

Article content

He said the lab had not tested the variant against blood from people who had received a booster dose, because they are not available in South Africa yet.

According to the manuscript, the lab observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.

Sigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.

While neutralizing antibodies are an indicator of the body’s immune response, scientists believe other kinds of cells such as B-cells and T-cells are also stimulated by the vaccines and help protect against the effects of the coronavirus.

The preliminary data does not indicate that the vaccine is less able to prevent severe illness or death. While lab tests are under way, BioNTech CEO Ugur Sahin said last week “we think it’s likely that people will have substantial protection against severe disease caused by Omicron.”

There is not significant data yet on how vaccines from Moderna, Johnson & Johnson and other drugmakers hold up against the new variant. All the manufacturers, including Pfizer and BioNTech, are expected to release their own data within weeks.

BioNTech’s Sahin told NBC News on Tuesday that the drugmaker has data coming on Wednesday or Thursday.

Advertisement

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Adblock test (Why?)



Source link

Continue Reading

Health

Omicron-specific vaccine likely to come too late to help in this wave: Sharma – Victoria News

Published

 on


Health Canada’s chief medical adviser says variant-specific vaccines can be approved faster than the general ones first issued to combat COVID-19, but one targeting the Omicron strain still likely won’t be ready in time to help with the latest wave.

Dr. Supriya Sharma said what is really needed are vaccines that can possibly stop more than one variant at a time, including those yet to come.

Omicron became the dominant variant in Canada in just over two weeks, and the Public Health Agency of Canada said Friday it’s now believed to be responsible for more than 90 per cent of all COVID-19 cases.

Studies suggest two doses of the existing mRNA vaccines from Pfizer-BioNTech and Moderna are not good at preventing infection from Omicron.

Multiple studies, however, suggest the vaccines are excellent at keeping symptoms mild, preventing hospitalizations, and shortening the stay and lowering the level of care for those who do get admitted to hospital. Fewer vaccinated Omicron patients, for example, need mechanical ventilation.

Both Pfizer and Moderna are working on new versions of their vaccines that specifically target the Omicron variant.

Moderna is hoping to get its product into trials early this year. Pfizer said it could have 100 million doses of theirs ready as early as March, and Canada has contracts for boosters from both companies that would include vaccines for variants too.

But Sharma said even with the expedited review process for vaccine variants, that’s “probably not” fast enough.

“By that time, based on what we’ve known about the Omicron wave, it might well and truly be through,” she said. “And then the question is always, ‘is there another variant that’s coming up?’”

The solution, she said, likely lies with vaccines that can target more than one variant at a time.

READ MORE: Omicron may seem unavoidable, but experts say ‘let it rip’ isn’t the solution

The COVID-19 vaccine technical committee of the World Health Organization said the same thing on Jan. 11, noting Omicron is the fifth variant of concern in two years and “is unlikely to be the last.”

Booster shots that heighten antibody development became the immediate response to Omicron for many governments, including Canada.

Dr. Srinivas Murthy, a British Columbia pediatrician and co-chair of the WHO’s clinical research committee on COVID-19, told The Canadian Press that boosters aren’t a long-term viable option.

“Boosting your way out of a pandemic is going to inevitably shoot you in the foot in the sense that you’re going to have a future variant that’s going to emerge that’s going to cause problems,” he said. “It’s going to evade your vaccines, and then you’re going to have to scramble.”

Omicron doesn’t evade the existing vaccines entirely but a future variant could, he said. The issue largely stems from the fact that the original vaccines train the body’s immune system to recognize what is called the spike protein found on the surface of a virus, and that spike protein is mutating significantly.

Think of the mutated spike protein as a bit of a disguise that makes it harder for the immune system to recognize the virus and mount a defence to kill it off.

Omicron has more than 50 mutations, and at least 36 are on the spike protein.

Multivalent vaccines that use the spike protein from more than one variant, or that target the genetic components of a virus rather than the spike protein, are possibly the ones that could offer protection for both this pandemic and the next novel coronavirus that emerges.

“It’s pan-coronavirus, where it’s looking at big broad neutralizing responses and you don’t have to update it every season and so on,” said Murthy. “That’s been the Holy Grail of flu vaccinology for the past number of decades. We haven’t achieved that yet, because flu is a bit tricky, but we think that it’s achievable for coronavirus, specifically.”

The United States Army has a version heading into Phase 2 trials that can attach multiple spike proteins. A vaccine with the specific spike proteins from all five COVID-19 variants of concern would likely be more successful, even against future variants, because they all share some of the same mutations and what one might miss another may catch.

Moderna is working on trials for multivalent vaccines using combinations of the spike proteins from the original virus and one of the variants, or two of the variants together. It’s not clear when they would be ready for use.

Sharma said even if the vaccines aren’t working as well against variants as they were against the original virus, to her “they’re still miraculous.”

“To have a vaccine that was developed that quickly, that still has, through multiple variants … with boosters, up to 70, 80 per cent effectiveness against serious disease, ailments, hospitalization and death,” she said. “That is miraculous for a new vaccine for a new virus.”

Mia Rabson, The Canadian Press


Like us on Facebook and follow us on Twitter.

Coronavirus

Adblock test (Why?)



Source link

Continue Reading

Health

Canada approves Pfizer’s oral COVID-19 antiviral treatment, seeks supplies

Published

 on

Canada on Monday approved Pfizer Inc’s oral antiviral treatment for mild to moderate cases of COVID-19 in people aged 18 and older but said supply shortages would keep doses from being made available immediately.

Infections and hospitalizations due the Omicron variant have been rising in Canada, forcing provinces to put in restrictions and the federal government to support impacted businesses.

“(This) is particularly important, as access to easy to use treatments could help to reduce the severity of COVID-19 in adults who become newly infected at high risk of progressing to serious illness,” said chief public health officer Theresa Tam.

Pfizer’s two-drug antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company’s clinical trial.

It is meant to be taken at home for five days beginning shortly after onset of symptoms.

Ottawa said last month it had signed a deal with Pfizer for a million treatment courses, pending approval. But getting those supplies could face hurdles.

“While there is currently limited global supply of Paxlovid, we are working to firm up a delivery schedule with the intent of bringing treatment courses to Canada as quickly as possible,” Tam told a briefing.

Ontario, the most populous of the 10 provinces, is seeing signs that Omicron cases may have peaked, said chief medical officer Kieran Moore.

“I’m starting to have much more hope … the number of cases is decelerating instead of accelerating in terms of hospitalizations and (people admitted to) intensive care units,” he told an Ottawa radio station.

Official data show that as of Jan 8, 87.8% of Canadians aged 12 and above had received two doses of a COVID-19 vaccine.

The U.S. authorized the Pfizer treatment for people ages 12 and older last month.

Canada is still looking at whether to approve Merck & Co’s oral antiviral pill, molnupiravir, which had less impressive results than Paxlovid in its pivotal clinical trial.

(Reporting by David Ljunggren in Ottawa and Ismail Shakil in Bengaluru; Editing by Franklin Paul and Bill Berkrot)

Continue Reading

Health

January 16, 2022 coronavirus update for Oakville – Oakville News

Published

 on


This is Oakville’s coronavirus update for Sunday, Jan. 16, 2022. As children head back to school tomorrow, the main takeaway from today’s COVID-19 update is the increase in the number of outbreaks in long-term care, retirement, and hospital facilities. OTMH is now dealing with two outbreaks as a new one was declared at 5 South, and the province has 231 hospitals recording ongoing outbreaks, an increase nice.

Hospital status

A new outbreak at OTMH was declared but not shown on the region’s update of Friday, Jan. 14, 2022. Halton does not provide new information on weekends or holidays. 

  • Oakville – 70 patients – plus 6
  • Halton – 126 patients – plus 10
  • Ontario – 3,595 patients – minus 362 (ICU 563 plus 19, Ventilators 327 plus 19)

Outbreaks

There are currently nine active outbreaks with 58 cases (LTC-41, retirement homes-13, hospitals-2) in Oakville. 

Ontario

Long-term care facilities status

  • 424 ongoing outbreaks -plus 9
  • 27,391 cases – plus 320
  • 39,06 resident deaths – plus 9

Retirement homes

  • 319 ongoing outbreaks – plus 16

Hospitals

  • 231 ongoing outbreaks – plus 16

Vaccination status

Halton 

  • 1st Dose (5+) – 90%
  • 2nd Dose (5+) – 83%
  • Boosters (18+) – 48%

Ontario administered 117,300 vaccinations

  • 1st Dose (5+) – 82%
  • 2nd Dose (5+) – 3%

Case status

The number of confirmed new cases in Oakville, Halton and Ontario is under-reported since the province restricted access to testing, limiting it to high-risk individuals, healthcare providers, and patients. 

Halton

  • 36,184 cases – plus 552 or 5,962.2 cases per million
  • 634.6 new weekly cases per 100,000, down 15.9 per cent from 2 weeks ago

Ontario

  • 948,086 total cases – plus 10,450 or 6,434.7 cases per million
  • 503.1 new weekly cases per 100,000, down 22.4 per cent from 2 weeks ago
  • 843,073 recoveries –  plus 15,317
  • 10,605 deaths – plus 40
  • 94,408 active cases – minus 4,907

**Vaccine booking: Halton continues to book first and second-dose vaccinations for all residents age five and older, plus third-dose boosters for all adults age 18 and up.

Parents must make booster doses and appointments for children in advance, but first and second doses for those 12 and up are available on a walk-in basis.

All vaccines approved for use in Canada effectively protect you against COVID-19 and all known variants of concern.

CLICK HERE to book a first, second or third vaccination appointment at a Halton Region vaccine clinic

The evidence is clear: vaccination is the best way to be protected. Local, provincial, national and international health units all affirm the same data that Canada’s approved vaccines effectively protect you from COVID-19 and significantly reduce your risks of getting sick, going to the hospital, and dying from the disease.

Pictured right is a graph from the Halton region showing how dramatically your risk of getting sick or being admitted to hospital is when vaccinated.

Sources: 

Adblock test (Why?)



Source link

Continue Reading

Trending